• Patient-Derived Gastric Cancer Assembloids

  2026-08-20

  Shapira-Netanelov and colleagues developed patient-matched gastric cancer assembloids that combine tumor organoids with stromal subpopulations derived from the same tissue. The model captures tumor–stroma effects on gene expression and drug sensitivity, providing a more physiologically informative platform for resistance studies and personalized therapeutic testing.

• Palbociclib (PD0332991): Applied Research Workflows

  2026-08-20

  Build reproducible Palbociclib assays around CDK4/6–Rb signaling, G0/G1 arrest, and apoptosis readouts. This practical guide also translates ERCC1–p53 DNA-repair findings into hypothesis-driven cell-cycle experiments for breast cancer and renal cell carcinoma research.

• CCK-8 Workflow for Ovarian Cancer Cell Studies

  2026-08-19

  Build a sensitive, low-complexity cck8 workflow for measuring ovarian cancer cell growth, viability, and treatment response. This guide connects Cell Counting Kit-8 readouts with SRSF9 perturbation, NUMB splicing analysis, and practical troubleshooting.

• Superoxide as a Translational Decision Signal

  2026-08-19

  Superoxide measurement can do more than document oxidative stress: it can help researchers connect environmental injury, inflammatory signaling, and therapeutic rescue. This thought-leadership guide uses recent DON immunotoxicity findings to show how a DHE-based workflow can strengthen mechanistic validation while clarifying the limits of fluorescence as a translational endpoint.

• Agatoxin-IVA Calcium Channels in Cardiac Vagal Neurons

  2026-08-18

  Wang, Irnaten, and Mendelowitz showed that nicotine activates cardiac vagal neurons through agatoxin-IVA-sensitive voltage-dependent calcium channels at both presynaptic and postsynaptic sites. Their patch-clamp pharmacology separates P-type channel involvement from a supporting, context-dependent contribution of L-type channels to glutamatergic transmission.

• SARS-CoV-2 NSP15 Screening: Thymopentin and Oleuropein

  2026-08-18

  The 2021 reference study used structure-based virtual screening and molecular-dynamics simulations to prioritize thymopentin and oleuropein as candidate inhibitors of the SARS-CoV-2 NSP15 endoribonuclease. Its main value is hypothesis generation: the results identify a viral immune-evasion target and computationally stable natural-product complexes, but biochemical, cellular, pharmacokinetic, and clinical validation remain necessary.

• ERCC1 Deficiency, p53, and Cisplatin Tolerance

  2026-08-17

  Heyza et al. used CRISPR-Cas9-engineered lung cancer models to show that ERCC1 loss produces strongly context-dependent responses to cisplatin, with p53 status determining apoptosis and cellular survival. The findings help explain why ERCC1 expression alone has performed inconsistently as a platinum-response biomarker and identify DNA-PKcs and BRCA1 as contributors to tolerance in ERCC1-deficient cells.

• Bortezomib (PS-341) Experimental Workflows

  2026-08-17

  Use Bortezomib (PS-341) as a reversible 20S proteasome perturbation tool for apoptosis assays, cancer models, and mechanistic studies of fibroblast migration. This workflow connects proteostasis with the TP–CTGF remodeling axis while separating evidence from the 2024 nasal fibroblast study from testable experimental extensions.

• HNF4A-AS1, Lipid Metabolism, and Sorafenib Resistance

  2026-08-16

  A 2024 Theranostics study identifies liver-enriched lncRNA HNF4A-AS1 as a regulator of sorafenib-induced ferroptosis in hepatocellular carcinoma. The work connects HNF4A-AS1, METTL3-dependent m6A modification, DECR1 degradation, and intracellular polyunsaturated fatty acids, offering a mechanistic explanation for lipid-metabolism-driven drug resistance.

• Palbociclib (PD0332991) Assay Workflows

  2026-08-15

  Build more interpretable CDK4/6 experiments with Palbociclib (PD0332991), from rapid Rb-pathway confirmation to cell-cycle, viability, and apoptosis readouts. This workflow also shows how to use the compound as a mechanistic comparator in breast, renal, and colorectal cancer models without mistaking cytostasis for cell death.

• Nuclear cGAS, Chk2, and L1 Genome Defense

  2026-08-14

  The reference study identifies a DNA damage-responsive pathway in which nuclear cGAS promotes TRIM41-dependent ubiquitination and degradation of L1 ORF2p, restricting retrotransposition and protecting genome integrity. Its findings connect CHK2-mediated cGAS phosphorylation with transposable-element control, while also providing a framework for studying how this axis may be altered during senescence and tumorigenesis.

• BMS-345541 Hydrochloride: Mechanism to Assay

  2026-08-14

  BMS-345541 hydrochloride is a selective IKK inhibitor for separating NF-κB transcription from RIPK1-linked cell death. This guide translates pathway biology into assay decisions for inflammation research, T-ALL, and mechanistic cancer biology.

• Ertugliflozin Cardiovascular Outcomes in Type 2 Diabetes

  2026-08-13

  The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its rigorous event-driven design also provides useful context for interpreting heart-failure, renal, safety, and translational SGLT2 research findings.

• LY2603618: Chk1 Inhibitor Workflow Guide

  2026-08-13

  LY2603618 provides a focused way to interrogate checkpoint kinase 1, G2/M control, and chemotherapy-associated DNA damage in cancer models. This guide connects practical dosing and readouts with a hypothesis-generating L1 retrotransposition workflow based on nuclear cGAS biology.

• Aurora Kinase A in High-Risk Retinoblastoma

  2026-08-12

  The 2024 reference study identifies AURKA overexpression as a molecular feature of human retinoblastoma associated with histopathologic high-risk factors and poor chemotherapy response. By combining patient-tissue analysis with genetic depletion, pharmacologic inhibition, patient-derived models, xenografts, and enucleated specimens, the investigators provide a rationale for evaluating selective Aurora A inhibition in advanced or refractory disease.

8070 records 2/538 page Previous Next 12345 下5页 Last page